Loading...
XJPX
4548
Market cap238mUSD
Dec 05, Last price  
678.00JPY
1D
-1.31%
1Q
0.15%
Jan 2017
-60.85%
IPO
15.57%
Name

Seikagaku Corp

Chart & Performance

D1W1MN
XJPX:4548 chart
P/E
30.48
P/S
0.94
EPS
22.24
Div Yield, %
4.13%
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
6.57%
Revenues
39.37b
+8.73%
23,144,000,00024,353,000,00027,630,000,00027,207,000,00027,617,000,00027,117,000,00027,082,000,00026,639,000,00029,614,000,00029,522,000,00030,962,000,00029,589,000,00030,175,000,00028,384,000,00028,642,000,00027,662,000,00034,851,000,00033,456,000,00036,213,000,00039,374,000,000
Net income
1.21b
-44.46%
4,677,000,0003,534,000,0004,243,000,0003,175,000,0003,575,000,0002,451,000,0003,270,000,0003,256,000,0004,745,000,0003,650,000,0002,578,000,0001,787,000,0003,922,000,0002,244,000,000-10,839,000,0004,262,000,0003,733,000,0002,236,000,0002,186,000,0001,214,000,000
CFO
4.43b
+763.35%
6,540,000,0002,286,000,0006,744,000,0002,891,000,0008,455,000,0004,819,000,0005,542,000,0004,345,000,0006,406,000,0004,132,000,0005,595,000,0004,885,000,0005,346,000,0003,121,000,0008,670,000,0001,257,000,0008,192,000,0001,574,000,000513,000,0004,429,000,000
Dividend
Mar 30, 202615 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
IPO date
Mar 23, 2004
Employees
976
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT